136 related articles for article (PubMed ID: 23273364)
1. Time-related changes in salivary levels of the osteotropic factors sRANKL and OPG through orthodontic tooth movement.
Flórez-Moreno GA; Isaza-Guzmán DM; Tobón-Arroyave SI
Am J Orthod Dentofacial Orthop; 2013 Jan; 143(1):92-100. PubMed ID: 23273364
[TBL] [Abstract][Full Text] [Related]
2. Screening for salivary levels of deoxypyridinoline and bone-specific alkaline phosphatase during orthodontic tooth movement: a pilot study.
Flórez-Moreno GA; Marín-Restrepo LM; Isaza-Guzmán DM; Tobón-Arroyave SI
Eur J Orthod; 2013 Jun; 35(3):361-8. PubMed ID: 22247225
[TBL] [Abstract][Full Text] [Related]
3. Salivary levels of Osteoprotegerin and receptor activator of nuclear factor-kappa ligand during orthodontic tooth movement-A prospective pilot study.
Naoumova J; Olofsson R; Almståhl A; Cevik-Aras H
Orthod Craniofac Res; 2024 Feb; 27(1):78-83. PubMed ID: 37381979
[TBL] [Abstract][Full Text] [Related]
4. [Indication of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa B ligand (RANKL) in gingival crevicular fluid to remodeling of alveolar bone during retention].
Zhao NN; Lin JX; Chen ZB; Liu Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Feb; 44(1):108-12. PubMed ID: 22353912
[TBL] [Abstract][Full Text] [Related]
5. Association of salivary levels of the bone remodelling regulators sRANKL and OPG with periodontal clinical status.
Tobón-Arroyave SI; Isaza-Guzmán DM; Restrepo-Cadavid EM; Zapata-Molina SM; Martínez-Pabón MC
J Clin Periodontol; 2012 Dec; 39(12):1132-40. PubMed ID: 23039038
[TBL] [Abstract][Full Text] [Related]
6. Assessing salivary biomarkers for analyzing orthodontic tooth movement.
Umesan UK; Chua KL; Krishnan V
Am J Orthod Dentofacial Orthop; 2013 Apr; 143(4):446-7. PubMed ID: 23561400
[No Abstract] [Full Text] [Related]
7. Salivary soluble receptor activator of nuclear factor kappa B ligand/osteoprotegerin ratio in periodontal disease and health.
Tabari ZA; Azadmehr A; Tabrizi MA; Hamissi J; Ghaedi FB
J Periodontal Implant Sci; 2013 Oct; 43(5):227-32. PubMed ID: 24236245
[TBL] [Abstract][Full Text] [Related]
8. Effect of smoking on concentrations of receptor activator of nuclear factor kappa B ligand and osteoprotegerin in human gingival crevicular fluid.
Tang TH; Fitzsimmons TR; Bartold PM
J Clin Periodontol; 2009 Sep; 36(9):713-8. PubMed ID: 19570104
[TBL] [Abstract][Full Text] [Related]
9. Age of donor alters the effect of cyclic hydrostatic pressure on production by human macrophages and osteoblasts of sRANKL, OPG and RANK.
Evans CE; Mylchreest S; Andrew JG
BMC Musculoskelet Disord; 2006 Mar; 7():21. PubMed ID: 16519799
[TBL] [Abstract][Full Text] [Related]
10. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B
Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829
[TBL] [Abstract][Full Text] [Related]
11. Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients.
Carmona-Fernandes D; Santos MJ; Perpétuo IP; Fonseca JE; Canhão H
Arthritis Res Ther; 2011; 13(5):R175. PubMed ID: 22027240
[TBL] [Abstract][Full Text] [Related]
12. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.
Ziolkowska M; Kurowska M; Radzikowska A; Luszczykiewicz G; Wiland P; Dziewczopolski W; Filipowicz-Sosnowska A; Pazdur J; Szechinski J; Kowalczewski J; Rell-Bakalarska M; Maslinski W
Arthritis Rheum; 2002 Jul; 46(7):1744-53. PubMed ID: 12124857
[TBL] [Abstract][Full Text] [Related]
13. Soluble receptor activator of nuclear factor- kappaB Ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases.
Pulsatelli L; Dolzani P; Silvestri T; Caraceni P; Facchini A; Ravaglia G; Salvarani C; Melicòni R; Mariani E
Biogerontology; 2004; 5(2):119-27. PubMed ID: 15105586
[TBL] [Abstract][Full Text] [Related]
14. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis.
Ishii R; Morimoto A; Ikushima S; Sugimoto T; Asami K; Bessho F; Kudo K; Tsunematu Y; Fujimoto J; Imashuku S
Pediatr Blood Cancer; 2006 Aug; 47(2):194-9. PubMed ID: 16358318
[TBL] [Abstract][Full Text] [Related]
15. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS).
Kim HR; Lee SH; Kim HY
Rheumatology (Oxford); 2006 Oct; 45(10):1197-200. PubMed ID: 16567356
[TBL] [Abstract][Full Text] [Related]
16. [Significance of sRANKL/OPG ratio in diagnosis of multiple myeloma bone disease].
Xu DR; Su C; Zou WY; Xu HR; Huang S; Li J; Luo SK
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):376-80. PubMed ID: 20416172
[TBL] [Abstract][Full Text] [Related]
17. Saliva concentrations of RANKL and osteoprotegerin in smoker versus non-smoker chronic periodontitis patients.
Buduneli N; Biyikoğlu B; Sherrabeh S; Lappin DF
J Clin Periodontol; 2008 Oct; 35(10):846-52. PubMed ID: 18727653
[TBL] [Abstract][Full Text] [Related]
18. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
Kim JG; Kim JH; Lee DO; Kim H; Kim JY; Suh CS; Kim SH; Choi YM
Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
[TBL] [Abstract][Full Text] [Related]
19. RANK/RANKL/OPG during orthodontic tooth movement.
Yamaguchi M
Orthod Craniofac Res; 2009 May; 12(2):113-9. PubMed ID: 19419454
[TBL] [Abstract][Full Text] [Related]
20. LMS-based continuous pediatric reference values for soluble receptor activator of nuclear factor kappa B ligand (sRANKL) and osteoprotegerin (OPG) in the HARP cohort.
Tietze H; Pott V; Kanzelmeyer N; Memaran N; Baumann U; Mindermann C; Suhlrie A; Drube J; Melk A; Das AM; Schnabel D; Haffner D; Leifheit-Nestler M
Osteoporos Int; 2024 Mar; 35(3):533-542. PubMed ID: 37940696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
